Condition category
Infections and Infestations
Date applied
Date assigned
Last edited
Retrospectively registered
Overall trial status
Recruitment status
No longer recruiting
Publication status

Plain English Summary

Background and study aims
The human immunodeficiency virus (HIV) is a type of virus known as a retrovirus. HIV attacks and weakens the immune system, making it more difficult for a sufferer to fight infections. It is a highly contagious disease, through bodily fluids such as blood, semen and vaginal fluids. There is currently no cure for HIV, but there are a range of drug treatments that can allow people who are HIV positive to lead a long and full life. Antiretroviral therapy (ART) is the standard treatment for HIV, where at least three different antiretroviral (ARV) drugs are given at the same time. This treatment is very effective at suppressing the virus and stopping the development of the disease. When a person has been on ART, the amount of HIV present in the blood (viral load) is reduced. After three to six months of treatment, the viral load should have fallen to undetectable levels (undetectable viral load). A commonly used ART is Atripla, which contains the three drugs efavirenz, emtricitabine, and tenofovir. Although this treatment can be very effective, it can cause long-term health problems, specifically problems with the bones and kidneys. A possible reason for this is the Atripla treatment could lead to reduced levels of different vitamins and minerals in the body, such as vitamin D and calcium, which can affect hormone levels. The aim of this study is to find out if treating HIV patients with the ARV’s Darunavir/Ritonavir only (single-drug therapy) is less toxic for bones and kidneys than standard ART.

Who can participate?
HIV positive adults, currently taking Atripla, who have had an undetectable viral load in the last 6 months.

What does the study involve?
Participants are randomly allocated to one of two groups. Those in the first group continue their Aripla therapy, which involves taking the Atripla tablets (which contain efavirenz, emtricitabine, and tenofovir) daily for the 48 week study. Those in the second group stop taking their Aripla and take darunavir 800mg/ritonavir 100mg every day for 48 weeks. At the start of the study and then every month until 48 weeks, participants provide blood and urine samples in order to test kidney function and biomarkers (chemical indicators) of bone health.

What are the possible benefits and risks of participating?
Not provided at time of registration.

Where is the study run from?
St. Thomas’ Hosptial (UK)

When is the study starting and how long is it expected to run for?
October 2010 to October 2013

Who is funding the study?
Tibotec (Janssen-Cilag Ltd) (UK)

Who is the main contact?
Dr Julie Fox

Trial website

Contact information



Primary contact

Dr Julie Fox


Contact details

Harrison Wing
St. Thomas' Hospital
2nd Floor Lambeth Wing
Westminster Bridge Road
United Kingdom

Additional identifiers

EudraCT number number

Protocol/serial number


Study information

Scientific title

The metabolic impact of darunavir/ritonavir maintenance monotherapy after successful viral suppression with standard Atripla in HIV-1 infected patients: an unblinded, multicentre, randomised controlled trial



Study hypothesis

This project aims to assess the potential long-term advantages of switching HIV patients from the standard therapy (Atripla) to a different regimen of treatment (darunavir 800 mg/ritonavir 100 mg) in terms of Vitamin D levels, calcium and phosphate homeostasis, renal (tubular) function, bone turnover and bone mineralisation and infection disease progression.

On 07/05/2014 the anticipated start date was changed from 01/03/2012 to 01/10/2014.

Ethics approval

Central London Research Ethics Committee 4, 04/08/2010

Study design

Multicentre open-label randomised controlled trial

Primary study design


Secondary study design

Randomised controlled trial

Trial setting


Trial type


Patient information sheet

Not available in web format, please use contact details below to request a patient information sheet




At baseline, patients will be randomised to receive either
1. Darunavir 800mg/ritonavir 100mg daily
2. Atripla® daily
Study medication/HIV regimen will be dispensed at each study visit.

All participants will have the opportunity to discuss continuing their study drug with their routine clinician at study end.

Intervention type



Phase IV

Drug names

Primary outcome measure

Change in 25(OH)Vitamin D

Secondary outcome measures

1. Reduction in parathyroid hormone levels
2. Improvements in serum calcium, phosphate, alkaline phosphatase
3. Improvement in estimated glomerular filtration rate, albuminuria and proteinuria, tubular phosphate reabsorption and other markers of renal tubular dysfunction
4. Improvement in bone mineral density
5. Immune activation: change in immune activation (CD8+CD38+)
6. The proportion of participants without therapeutic failure (defined as two consecutive HIV-RNA values > 50 copies/ml)

Outcomes will be measured throughout the study period though lab analysis will be carried out at end of the study. Samples will be blood/urine samples and for substudy, genital secretions.

Overall trial start date


Overall trial end date


Reason abandoned (if study stopped)


Participant inclusion criteria

1. Between 18-65 Males and Females
2. Documented Positive HIV-antibody test and previous positive HIV-antibody test within three months of the start of the study
3. Plasma HIV RNA <50 copies/ml for at least six months on Atripla
4. Agree to NOT take vitamin D supplements for the duration of the study
5. Willing to use barrier contraception (condoms) for the duration of their participation in the study
6. Ability to give informed consent

Participant type


Age group




Target number of participants


Participant exclusion criteria

1. Pregnancy or breast feeding
2. Patient unlikely to comply with protocol, and in particular adhere to therapeutic regimen
3. Patient likely to use narcotics during the study period
4. Hepatitis B co-infection (past or present)
5. Diabetes mellitus
6. Received vitamin D supplementation for more than one month within the previous 6 months
7. Current use or likely to require use of concomitant medication with known interactions with Darunavir or Ritonavir including rifampicin, amiodarone, flecainide, bupropion, clozapine, ergotamine, mexilitine, midazolam, pethidine, pimoziide, quinidine, sertindole, sildanefil, voriconazole, zolpidem, and St. John’s Wort would exclude a subject from the trial
8. Individuals experiencing side effects from their current regime will not be excluded from analysis

Recruitment start date


Recruitment end date



Countries of recruitment

United Kingdom

Trial participating centre

St. Thomas' Hospital
Harrison Wing 2nd Floor Lambeth Wing Westminster Bridge Road
United Kingdom

Sponsor information


Guy's & St. Thomas' NHS Foundation Trust (UK)

Sponsor details

16th Floor
Tower Wing
Guy's Hospital
Great Maze Pond
United Kingdom

Sponsor type

Hospital/treatment centre



Funder type


Funder name

Tibotec (Janssen-Cilag Ltd) (UK)

Alternative name(s)

Funding Body Type

Funding Body Subtype


Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Participant level data

Not provided at time of registration

Basic results (scientific)

Publication list

1. 2016 results of the effects on vitamin D, bone and the kidney when switching from fixed-dose tenofovir disoproxil fumarate/emtricitabine/efavirenz to darunavir/ritonavir monotherapy, in (added 21/01/2019)
2. 2016 results of switching from Atripla to darunavir/ritonavir Monotherapy on neurocognition, quality of life, and sleep, in (added 21/01/2019)
3. 2017 results in (added 21/01/2019)

Publication citations

Additional files

Editorial Notes

21/01/2019: Publication reference added 03/04/2018:No publications found, verifying study status with principal investigator. 29/01/2016: No publications found, verifying study status with principal investigator.